EUVIMEDEUVIMED entdecken
Crossref

MASLD and the cardiovascular-kidney-liver-metabolic syndrome

Angeliki M Angelidi iD, Chrysoula Boutari, Michail Kokkorakis, Konstantinos Stefanakis, Dimitri P Mikhailidis, George Jacob, Christos S Mantzoros iD

Endocrine Reviews · 15.07.2026

DOI: 10.1210/endrev/bnag023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Reviews, online erschienen am 15.07.2026. Verfasst von Angeliki M Angelidi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 630 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is an alarmingly growing global epidemic strongly associated with type 2 diabetes, cardiovascular disease, metabolic syndrome, and chronic kidney disease. Metabolic dysfunction-associated steatotic liver disease (MASLD) is considered an important contributor within this interconnected spectrum, representing a new component of the broader cardio-kidney-metabolic (CKM) syndrome, now more aptly labeled as the cardio-kidney-liver-metabolic (CKLM) syndrome. This narrative review synthesizes evidence from epidemiological studies, clinical trials, and ongoing scientific research to explore the multifaceted associations, complex interplay and shared pathophysiological mechanisms among these disorders. The clinical implications of this interplay are substantial, underscoring the need for a holistic approach encompassing early detection, comprehensive risk assessment, and multi-targeted interventions. Therapeutic strategies discussed include lifestyle modification, anti-diabetic, anti-obesity, lipid-lowering agents, and bariatric surgery. Given MASLD's potential role in the CKLM spectrum, future research should deepen the understanding of shared mechanisms and develop integrated clinical management strategies to improve outcomes and reduce their global burden.

Schlagwörter

Stichwörter der Autor:innen

cardiovascular diseasechronic kidney diseasedyslipidemiametabolic dysfunction-associated steatotic liver diseasemetabolic syndromeobesity

Autor:innen und Institutionen

  • Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Program in Metabolism, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Division of Surgery and Interventional Science, Department of Surgical Biotechnology, University College London Medical School, University College London (UCL), London, UK.
  • Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London (UCL), London, UK.

ORCID-Profile: Angeliki M Angelidi, Christos S Mantzoros

Zitieren

APA

Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026). MASLD and the cardiovascular-kidney-liver-metabolic syndrome. Endocrine Reviews. https://doi.org/10.1210/endrev/bnag023

Vancouver

Angelidi AM, Boutari C, Kokkorakis M, Stefanakis K, Mikhailidis DP, Jacob G, et al. MASLD and the cardiovascular-kidney-liver-metabolic syndrome. Endocrine Reviews. 2026. doi:10.1210/endrev/bnag023

BibTeX
@article{Angelidi2026,
  author = {Angelidi, Angeliki M and Boutari, Chrysoula and Kokkorakis, Michail and Stefanakis, Konstantinos and Mikhailidis, Dimitri P and Jacob, George and Mantzoros, Christos S},
  title = {MASLD and the cardiovascular-kidney-liver-metabolic syndrome},
  journal = {Endocrine Reviews},
  year = {2026},
  doi = {10.1210/endrev/bnag023}
}
Kostenlos starten →